Clinical disclaimer: This article is educational and does not constitute personal medical advice. If you take medication affected by weight change, or have type 2 diabetes, involve your clinician before making any changes. Never stop medication abruptly without clinical supervision.

The duration question is clinical, not personal

Patients often approach the question of how long to stay on GLP-1 medication as a personal decision — about discipline, commitment, or how much help they think they deserve. It is not. It is a clinical decision based on indication, response, cardiometabolic risk, tolerability, and the consequences of stopping. The right answer varies considerably by patient.

What NICE says

NICE guidance on tirzepatide (TA1026, 2025) specifies that treatment should be reviewed at two years. Continuation beyond two years is appropriate only if the patient has maintained at least 5% weight loss from baseline. [1] For semaglutide (Wegovy), similar continuation criteria apply. [2] These criteria are thresholds, not ceilings — they establish minimum effectiveness, not maximum duration.

The absence of a defined maximum duration in NICE guidance reflects the emerging understanding that obesity is a chronic condition requiring potentially long-term pharmacological management, not a finite course of treatment.

The case for long-term treatment

SURMOUNT-4 is the most compelling evidence for long-term tirzepatide treatment. Participants who continued had maintained and augmented weight loss at week 88; those who stopped had regained substantially. [3] The same pattern is seen with semaglutide in STEP 4 and the STEP 1 extension. [4,5] The trials consistently show: while the drug is present, benefits are maintained; when it is removed, benefits reverse. This biology supports long-term prescribing for patients with ongoing clinical need.

The cardiometabolic benefits — blood pressure, glucose, lipids, HbA1c — also reverse with weight regain. For patients with significant cardiovascular risk, this is not a trivial consideration. The SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide in patients with established cardiovascular disease and obesity. [6] Stopping treatment in such patients is a cardiometabolic intervention, not just a weight question.

Reasons to stop earlier than two years

Side effects that significantly impair quality of life and do not improve with dose adjustment. Surgical procedures that require preoperative cessation (GLP-1 agents increase aspiration risk with delayed gastric emptying; most anaesthetists now request stopping two to four weeks before elective general anaesthesia). Pregnancy planning. Inadequate response — less than 5% weight loss after sixteen weeks at therapeutic dose suggests the medication is not working for this patient. [1]

Reasons to continue longer than expected

Significant ongoing cardiometabolic benefit — maintained blood pressure reduction, HbA1c improvement, cardiovascular risk reduction. Personal history of significant weight regain after previous treatment cessation. Absence of side effects at the current dose. Ongoing clinical indication that predates the weight loss treatment (type 2 diabetes, for example).

The honest cost conversation

Private GLP-1 medication costs £150–200 per month at most doses. The question of how long to stay on medication is partly — honestly — a financial one for many patients. The clinical guidance is clear: if the medication is working and the indication remains, ongoing treatment is appropriate. The practical reality is that this must be weighed against cost and what alternatives exist. A structured review of the full picture — including what stopping would mean for blood pressure, glucose, and cardiometabolic risk — makes that decision more informed.

FAQ

How long should I stay on Mounjaro?
NICE guidance specifies review at two years; continuation beyond that requires maintained weight loss of at least 5% from baseline. There is no defined maximum duration — for patients with ongoing clinical need and good response, long-term treatment is clinically justified. The right duration is individual.
Can I take Wegovy forever?
Long-term treatment is not contraindicated and is appropriate for patients with ongoing clinical need. The evidence shows benefits are maintained during treatment and reverse after stopping — for patients with significant cardiovascular risk or metabolic disease, indefinite treatment may be clinically rational.
When should I stop GLP-1 medication?
Reasonable stopping points: reaching a clinically meaningful weight and metabolic target with a solid maintenance plan; side effects that do not resolve with dose adjustment; before elective surgery (two to four weeks); pregnancy planning; or less than 5% weight loss after sixteen weeks at therapeutic dose (indicating inadequate response).
Is it bad to stay on Mounjaro long-term?
The safety data for long-term tirzepatide and semaglutide use are reassuring at durations covered by trials (up to three to four years). No long-term safety signals of clinical concern have emerged. The theoretical risk of indefinite thyroid C-cell stimulation — relevant from rodent data — has not been demonstrated in human populations.
What if I cannot afford to stay on GLP-1 medication long-term?
This is a practical reality for many patients. If cost prevents ongoing treatment, the priority is a structured exit plan rather than unplanned stopping. A clinical review before stopping identifies the cardiometabolic variables most at risk and builds a monitoring plan for the transition.

References

  1. NICE. Tirzepatide for managing overweight and obesity. TA1026. 2025.
  2. NICE. Semaglutide for managing overweight and obesity. TA875. 2023.
  3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction: SURMOUNT-4. JAMA. 2024.
  4. Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: STEP 4 trial. JAMA. 2021.
  5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022.
  6. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. SELECT trial. N Engl J Med. 2023.